Global Blood Therapeutics (GBT) Trading Down 5.1% After Insider Selling

Shares of Global Blood Therapeutics Inc (NASDAQ:GBT) were down 5.1% during trading on Monday following insider selling activity. The company traded as low as $57.25 and last traded at $57.72. Approximately 746,681 shares were traded during trading, a decline of 41% from the average daily volume of 1,257,703 shares. The stock had previously closed at $60.80.

Specifically, insider Jung Choi sold 3,000 shares of the stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $36.55, for a total value of $109,650.00. Following the transaction, the insider now owns 135,255 shares in the company, valued at $4,943,570.25. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Perceptive Advisors Llc purchased 175,000 shares of the business’s stock in a transaction on Tuesday, December 19th. The stock was purchased at an average price of $38.00 per share, for a total transaction of $6,650,000.00. The disclosure for this purchase can be found here. In the last quarter, insiders sold 51,812 shares of company stock worth $2,864,728. Corporate insiders own 5.30% of the company’s stock.

Several research analysts have issued reports on GBT shares. Zacks Investment Research upgraded Global Blood Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, December 6th. Cowen restated a “buy” rating and issued a $83.00 target price on shares of Global Blood Therapeutics in a report on Thursday, November 9th. Wedbush restated an “outperform” rating and issued a $73.00 target price on shares of Global Blood Therapeutics in a report on Friday, December 15th. Nomura raised their target price on Global Blood Therapeutics to $91.00 and gave the company a “buy” rating in a report on Monday, December 11th. Finally, Oppenheimer set a $79.00 target price on Global Blood Therapeutics and gave the company a “buy” rating in a report on Tuesday, December 12th. Two investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Global Blood Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $63.27.

The company has a market capitalization of $2,670.00 and a price-to-earnings ratio of -22.73.

Global Blood Therapeutics (NASDAQ:GBT) last posted its earnings results on Thursday, November 2nd. The company reported ($0.66) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.04). During the same quarter in the prior year, the company posted ($0.58) earnings per share. equities research analysts predict that Global Blood Therapeutics Inc will post -2.53 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of GBT. Jane Street Group LLC purchased a new stake in shares of Global Blood Therapeutics during the third quarter valued at approximately $200,000. Trexquant Investment LP purchased a new stake in shares of Global Blood Therapeutics during the third quarter valued at approximately $202,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Global Blood Therapeutics during the third quarter valued at approximately $205,000. Virtu KCG Holdings LLC purchased a new stake in shares of Global Blood Therapeutics during the second quarter valued at approximately $219,000. Finally, Cubist Systematic Strategies LLC increased its position in shares of Global Blood Therapeutics by 94.7% during the second quarter. Cubist Systematic Strategies LLC now owns 8,205 shares of the company’s stock valued at $224,000 after acquiring an additional 3,991 shares during the last quarter. 85.67% of the stock is owned by institutional investors.

WARNING: This piece of content was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.com-unik.info/2018/02/07/global-blood-therapeutics-gbt-trading-down-5-1-after-insider-selling.html.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit